REFERENCES
- Mahler D A, Weinberg D H, Wells C K, Feinstein A R. The measurement of dyspnea: contents, inter-observer agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85:751–758. [PUBMED], [INFOTRIEVE]
- Mahler D A, Tomlinson D, Olmstead E M, Tosteson A NA, O'Connor G T. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med 1995; 151:61–65. [PUBMED], [INFOTRIEVE], [CSA]
- Casaburi R, Mahler D A, Jones P W, Wanner A, San Pedro G, ZuWallack R L, Menjoge S S, Serby C W, Witek T Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217–224. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Guyatt G H, Berman L B, Townshend M, Pugsley S O, Chambers L W. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42:773–778. [PUBMED], [INFOTRIEVE]
- Eakin E G, Resnikoff P M, Prewitt L M, Ries A L, Kaplan R M. Validation of a new dyspnea measure: the UCSD shortness of breath questionnaire. Chest 1998; 113:619–624. [PUBMED], [INFOTRIEVE]
- Mahler D A, Ward J, Fierro-Carrion G, Waterman L, Lentine T F, Mejia-Alfaro R, Baird J C. Development of self-administered versions of the modified baseline and transition dyspnea indexes in COPD. J COPD 2004; 1:165–172.
- Ries A L, Kaplan R M, Blumberg E. Use of factor analysis to consolidate multiple outcome measures in chronic obstructive pulmonary disease. J Clin Epidemiol 1991; 44:497–503. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mahler D A, Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength and lung function in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145:467–470. [PUBMED], [INFOTRIEVE]
- Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:1185–1189. [PUBMED], [INFOTRIEVE], [CSA]
- Mahler D A, Wells C K. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93:580–586. [PUBMED], [INFOTRIEVE]
- Guyatt G H, Thompson P J, Berlan L B, Sullivan M J, Townsend M, Jones N L, Pugsley S O. How should we measure function in patients with chronic heart and lung disease? J Chron Dis 1985; 38:517–524. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mahler D A, Matthay R A, Snyder P E, Wells C K, Loke J. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis 1985; 131:22–25. [PUBMED], [INFOTRIEVE]
- Kirsten D K, Wegner R E, Jorres R A, Magnussen H. Effects of theophylline withdrawl in severe chronic obstructive pulmonary disease. Chest 1993; 104:1101–1107. [PUBMED], [INFOTRIEVE]
- ZuWallack R L, Mahler D A, Reilly, Church N, Emmett A, Rickard K, Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119:1628–1630. [CROSSREF]
- Aalbers R, Ayres J, Backer V, Decramer M, Lier P A, Magyar P, Malolepszy J, Ruffin R, Sybrecht G W. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002; 19:936–943. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mahler D A, Donohue J F, Barbee R A, Goldman M D, Gross N J, Wisniewski M E, Yancey S W, Zakes B A, Rickard K A, Anderson W H. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957–965. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rennard S I, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1087–1092. [PUBMED], [INFOTRIEVE], [CSA]
- Vincken W, van Noord J A, Greefhorst A PM, Bantje T A, Kesten S, Korducki L, Cornelissen P JG. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J 2002; 19:209–216. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Brusasco V, Hodder R, Miravitlles M, Korducki L, Tlwse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58:399–404. [PUBMED], [INFOTRIEVE], [CROSSREF]
- O'Donnell D E, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium in lung hyperinflation, dyspnoea, and exercise tolerance in COPD. Eur Respir J 2004; 23:832–840. [PUBMED], [INFOTRIEVE]
- Mahler D A, Wire P, Horstman D, Chang C N, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084–1091. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hanania N A, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124:834–843. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Reardon J, Awad E, Normandin E, Vale F, Clark B, ZuWallack R L. The effect of comprehensive outpatient pulmonary rehabilitation on dyspnea. Chest 1994; 105:1046–1052. [PUBMED], [INFOTRIEVE]
- Goldstein R S, Gort E H, Stubbing D, Avendano M A, Guyatt G H. Randomised controlled trial of respiratory rehabilitation. Lancet 1994; 344:1394–1397. [PUBMED], [INFOTRIEVE], [CROSSREF]
- O'Donnell D E, McGuire M A, Samis L, Webb K A. The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. Am J Respir Crit Care Med 1995; 152:2005–2013. [PUBMED], [INFOTRIEVE], [CSA]
- O'Donnell D E, McGuire M, Samis L, Webb K A. General exercise training improves ventilatory and peripheral muscle strength and endurance in chronic airflow limitation. Am J Respir Crit Care Med 1998; 157:1489–1497. [PUBMED], [INFOTRIEVE], [CSA]
- Hernandez M TE, Rubio T M, Ruiz F O, Riera H S, Gil R S, Gomez J C. Results of a home-based training program for patients with COPD. Chest 2000; 118:106–114. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Behnke M, Taube C, Kirsten D, Lehnick B, Jorres R A, Magnussen H. Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. Respir Med 2000; 94:1184–1191. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ries A L, Kaplan R M, Myers R, Prewitt L M. Maintenance after pulmonary rehabilitation in chronic lung disease. Am J Respir Crit Care Med 2003; 167:880–888. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Harver A, Mahler D A, Daubenspeck J A. Targeted inspiratory muscle training improves respiratory muscle function and reduces dyspnea in patients with chronic obstructive pulmonary disease. Ann Intern Med 1989; 111:117–124. [PUBMED], [INFOTRIEVE]
- Lisboa C, Munoz V, Beroiza T, Leiva A, Cruz E. Inspiratory muscle training in chronic airflow limitation: comparison of two different training loads with a threshold device. Eur Respir J 1994; 7:1266–1274. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lisboa C, Villafranca C, Leiva A, Cruz E, Pertuze J, Borzone G. Inspiratory muscle training in chronic airflow limitation: effect on exercise performance. Eur Respir J 1997; 10:537–542. [PUBMED], [INFOTRIEVE]
- Scherer T A, Spengler C M, Owassapian D, Imhof E, Boutellier U. Respiratory muscle endurance training in chronic obstructive pulmonary disease: impact on exercise capacity, dyspnea, and quality of life. Am J Respir Crit Care Med 2000; 162:1709–1714. [PUBMED], [INFOTRIEVE], [CSA]
- Riera H S, Rubio T M, Ruiz F O, Ramos P C, del Castillo Otero D, Hernandez T E, Gomez J C. Inspiratory muscle training in patients with COPD. Chest 2001; 120:748–756. [CROSSREF]
- Weiner P, Magadle R, Beckerman M, Weiner M, Berar-Yanay N. Maintenance of inspiratory muscle training in COPD patients: one year follow-up. Eur Respir J 2004; 23:61–65. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Witek T J Jr, Mahler D A. Meaningful effect size and patterns of response of the Transition Dyspnea Index. J Clin Epidemiol 2003; 56:248–255. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Witek T J Jr, Mahler D A. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003; 21:1–6.
- Norman G R, Sloan J A, Wyrwich K W. Interpretation of changes in health-related quality of life. Med Care 2003; 41:582–592. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Guyatt G H, Osoba D, Wu A W, Wyrwich K W, Norman G R. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77:371–383. [PUBMED], [INFOTRIEVE], [CSA]